A bill to establish procedures for the removal of the Architect of the Capitol.
Impact
The introduction of SB97 represents a significant change in the governance of the Capitol’s oversight responsibilities. Currently, removal of the Architect lacks a structured process, which can lead to uncertainties during times of disagreement over performance or conduct. By instituting a clear set of criteria and procedures for removal, SB97 aims to ensure that the Architect remains accountable to Congress while also safeguarding the integrity of the Capitol's operations. Proponents argue that it is essential for maintaining standards within this critical role, addressing potential inefficiencies or misconduct head-on.
Summary
SB97 is a legislative proposal aimed at establishing formal procedures for the removal of the Architect of the Capitol. This bill proposes to amend the Legislative Branch Appropriations Act of 1990 by clearly outlining the circumstances under which the Architect can be removed. The new stipulations include grounds such as permanent disability, inefficiency, neglect of duty, malfeasance, or any felony or conduct involving moral turpitude. This measure seeks to enhance accountability in the role of the Architect, aligning it with other positions in government that have defined removal processes.
Contention
The bill is expected to face scrutiny and discussion concerning the delineation of the responsibilities and authority of Congress in the removal process. Some members of Congress may argue that the criteria for removal are perhaps too vague, potentially enabling politically motivated removals. Furthermore, opponents of the bill may express concern over the implications for autonomy within the Architect's office, noting that frequent changes in leadership could disrupt ongoing projects and undermine long-term planning. The balance between accountability and stability within this critical office will likely be a focal point during legislative discussions.
To provide for a limitation on availability of funds for Joint Items, Architect of the Capitol, Capital Construction and Operations for fiscal year 2024.
Establishing deadlines for the Joint Committee of Congress on the Library to approve or deny the statue of the Reverend William Franklin "Billy" Graham, Jr., for placement in the National Statuary Hall.
Article I Regulatory Budget Act This bill requires the establishment of a federal regulatory budget to limit the costs of federal regulations. It also establishes requirements for disclosing the projected costs of federal regulations and procedures for enforcing the regulatory budget.
Buy Low and Sell High Act This bill revises requirements concerning the Strategic Petroleum Reserve (SPR) and sets forth provisions to reduce the demand for petroleum fuel and increase fuel supply. For example, the bill directs the Department of Energy (DOE) to establish within the SPR an Economic Petroleum Reserve of up to 350 million barrels of crude oil. DOE must also establish a national network of Strategic Refined Petroleum Product Reserves to store up to 250 million barrels of gasoline and diesel fuel, which may be sold when there is a severe fuel supply interruption within the district in which the reserve is located. In addition, the bill increases the cap on the amount of barrels of petroleum distillate that may be stored in the Northeast Home Heating Oil Reserve from two million to four million. It also establishes limits on the sale and exportation of petroleum products from such reserves. Further, the bill establishes provisions concerning electrifying the transportation sector, zero-emission vehicles, and a program to increase the amount of crude oil refined in oil refineries in certain countries in the Western Hemisphere.
Interagency Patent Coordination and Improvement Act of 2023 This bill establishes the Interagency Task Force on Patents to support coordination and communication between the U.S. Patent and Trademark Office (PTO) and the Food and Drug Administration (FDA) on activities relating to patents for human drugs and biological products. The task force's duties shall include sharing information about (1) the processes of each agency, including how each agency evaluates applications (e.g., patent applications at the PTO and new drug applications at the FDA); and (2) new approvals of patents, human drugs, biological products, and new technologies. The task force must also establish a process that requires (1) the PTO to request from the FDA information relating to certain patent applications to help patent examiners carry out their duties, (2) the FDA to provide such information to the PTO, and (3) the PTO to assist the FDA in its ministerial role of listing patents.